Technology to inhibit vascular changes that lead to vision loss in the eye

Patent metadata

Field	Value
Publication number	US-10588916-B2
Application number	US-201816160840-A
Country	US
Kind code	B2
Filing date	Oct 15, 2018
Priority date	Oct 31, 2017
Publication date	Mar 17, 2020
Grant date	Mar 17, 2020

Abstract

This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

First claim

The invention claimed is:

1. A method of inhibiting vaso-obliteration that leads to vision loss in an eye of a subject in need thereof, comprising administering to the eye a pharmaceutical composition comprising an effective amount of a compound, wherein the compound is BM-1197.

2. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in inhibiting pathogenic angiogenesis in the eye.

3. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in inhibiting retinal neovascularization in the eye.

4. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in inhibiting retinal or choroidal vascular leakage in the eye.

5. The method of claim 1 , wherein the amount of the compound in the pharmaceutical composition that is administered to the eye is also effective in promoting repair of functional vasculature in the eye.

Assignees

• Unity Biotechnology Inc

Inventors

• Tsuruda Pam
• Hopkins Jill
• Sweigard Harry
• Poon Yan
• Dananberg Jamie
• Marquess Daniel
• David Nathaniel

Classifications

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title